Yi Zhang

发表

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis

John D. Davis, A. Paller, E. Simpson, 2021, Clinical pharmacology and therapeutics.

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.

M. Krempf, P. Hopkins, E. Bruckert, 2019, Journal of clinical lipidology.

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.

A. Catapano, M. Harada‐Shiba, Shazia Ali, 2020, Atherosclerosis.

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

John D. Davis, N. Al-Huniti, M. Sale, 2021, CPT: pharmacometrics & systems pharmacology.

Evinacumab for Homozygous Familial Hypercholesterolemia.

D. Gaudet, G. Yancopoulos, R. Rosenson, 2020, The New England journal of medicine.

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.

I. Pavord, H. Watz, M. Wechsler, 2021, The Lancet. Respiratory medicine.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study

Haiyan Li, M. Baccara-Dinet, Yi Zhang, 2020, American Journal of Cardiovascular Drugs.

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

John D. Davis, N. Al-Huniti, J. Bosley, 2021, CPT: pharmacometrics & systems pharmacology.

Patient-Reported Outcomes from a Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

R. Kelly, Yi Zhang, D. Rofail, 2022, Blood.